WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Prof. Dr. Gamal Abdul Hamid*


Treatment of chronic myeloid leukemia (CML) with target therapy approved 5 different tyrosine kinase inhibitors (TKIs; imatinib, nilotinib, dasatinib, bosutinib and ponatinib) according to the disease risk, disease stage, comorbidities and BCR-ABL genotype. Imatinib was the most common drug of choice for treatment of newly diagnosed CML patients in the last 15 years. In the last 3 years nilotinib, dasatinib and bosutinib, three newer drugs with higher potency against BCRABL and against imatinib-resistant BCR-ABL mutations. Ponatinib is the newest TKI indicated for chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant or intolerant to dasatinib, nilotinib or bosutinib. Allogenic stem cell transplantation is a curative treatment for patients with CML, but the excellent curative remission with TKI therapy have challenged the role of allogeneic stem cell transplantation as a first line therapy.

Keywords: Chronic myeloid leukemia, Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More